Pharma Firms May Be Due A Refund Under UK Voluntary Price Scheme
Executive Summary
Companies that chose to stay in the UK’s voluntary pricing scheme (VPAS) could be entitled to a refund on their rebate payments, while those that have left may end up paying more.
You may also be interested in...
Investment In Medicines Manufacturing Must Be UK Priority
New report on UK medicines manufacturing advises the government to improve voluntary scheme on medicine pricing to drive growth.
UK Govt Casts Industry Concerns Aside And Confirms Rise In Statutory Scheme Rebate
The UK government is standing its ground on this year’s hike in the statutory pricing scheme rebate, despite industry worries about the impact on companies’ investment decisions.
Older Medicines Rebate Will Test UK’s New Pricing & Access Scheme
As the UK government implements a new rebate system for older medicines as part of the new pricing deal, industry trade bodies and experts suggest that exceptions will have to be made, such as higher prices or lower rebate levels for specific products.